Drug Type Small molecule drug, Diagnostic radiopharmaceuticals |
Synonyms [18F]JHU-82132 |
Target |
Mechanism α7 receptor antagonists(Neuronal acetylcholine receptor protein alpha-7 subunit antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC19H19FN2O2S |
InChIKeyJIGWWGDIEUWCOR-LRFGSCOBSA-N |
CAS Registry1456878-52-6 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Schizophrenia | Phase 1 | US | 18 Aug 2022 | |
Tobacco Use Disorder | Phase 1 | US | 16 Dec 2019 | |
Psychotic Disorders | Phase 1 | - | - | |
Psychotic Disorders | Phase 1 | - | - |
Phase 1 | 15 | rqbjjtkjey(wofacmqvbk) = ekgynpqnbu zhtrmccdph (vzkrrwvvmi, smzzrhvgtk - brqqagekxq) View more | - | 06 Aug 2024 | |||
Not Applicable | - | - | (Test-retest group) | uuggcarfrj(kkzatcrlxf) = xrcfscotmv ekplftjuxd (fkpiqxaicx ) | - | 24 May 2017 | |
DXMB-A pre-treated group | hbsjnuvxdc(vzsgmouyif) = vvznrugkxa uskkpevodr (sduyimjxua ) |